Skip to search formSkip to main contentSkip to account menu

monoclonal antibody BIWA 4

Known as: BIWA 4 (MAb), bivatuzumab 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
SHIZENGAKU [BIWA/BIWAKO]: SONIC COMPLEMENT, COUNTERPOINT OR INTERPENETRATION?
This copy has been supplied on the understanding that it is copyright material. Duplication or sale of all or part of any of the… 
2013
2013
Drug targeting , Pharmacokinetics and Biodistribution : Differences between species
SUMMARY Hyaluronan (HA)-binding proteins, such as the cell-surface CD44 proteoglycan family and the Receptor for Hyaluronoan… 
2010
2010
Case note: Rb. Den Haag (nr. 08/05396, LJN BL4476: ongedaan maken investering leidt niet tot desinvesteringsbijtelling)
Belanghebbende vormt samen met haar dochtervennootschap, Y bv, een fiscale eenheid. Y bv heeft in 2002 een projectontwikkelaar de… 
2007
2007
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
2003
2003
Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
UNLABELLED From December 1999 until July 2001, a phase I dose escalation study was performed with (186)Re-labeled bivatuzumab, a… 
2000
2000
TONAI Kakuryo, Nihon kindai biwa no kenkyu: Toriguchi, shirabeguchi wo chushin to shita “sawari” no ongaku kozo
1983
1983
Biwa-Hoshi : From the Viewpoint of "Marebito" Theory Part I
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)